Vanderbilt researchers, including Hematology and Oncology Drs. Justin Balko, Brian Lehmann and Vandana Abramson, have discovered a druggable target on natural killer cells that could potentially trigger a therapeutic response in patients with immunotherapy-resistant, triple-negative breast cancer.
The Robert J. Kleberg, Jr. and Helen C. Kleberg Foundation has funded an ambitious initiative to overcome one of the most perplexing and frustrating mysteries of cancer treatment — how to prevent drug resistance. The three-year grant was awarded to Hematology and Oncology Dr. Ben Ho Park and Biochemistry Dr. Houra Merrikh.
Seven new leaders have been appointed to guide Vanderbilt-Ingram Cancer Center’s research programs. Martha Shrubsole, PhD (Epidemiology), joins Xiao-Ou Shu, MD, PhD, MPH, Ingram Professor of Cancer Research (Epidemiology), as a co-leader of the Cancer Epidemiology Research Program. Vandana Abramson, MD (Hematology and Oncology), joins Justin Balko, PharmD, PHD (Hematology and Oncology), as a co-leader of the Breast Cancer Research Program.
Vanderbilt’s Eden Biltibo, MD, MS, is one of the first recipients of the Multiple Myeloma Research Foundation’s Scholars Program, an initiative launched in 2022.
Kimryn Rathmell, MD, PhD, MMHC, the Hugh Jackson Professor of Medicine and chair of the Department of Medicine at Vanderbilt University Medical Center (VUMC), will be appointed Director of the National Cancer Institute (NCI).
Kimryn Rathmell, MD, PhD, chair of the Department of Medicine at Vanderbilt University Medical Center, has received the Paragon Award for Research Excellence from the Doris Duke Foundation (DDF).
Vanderbilt-Ingram Cancer Center (VICC) has earned a Merit Extension Award from the National Cancer Institute (NCI) in recognition of more than a decade of sustained exceptional progress.
A subset of side effects continued to improve over time,” said the study’s senior author, Douglas Johnson, MD, MSCI, clinical director of melanoma at Vanderbilt-Ingram Cancer Center and holder of the Susan and Luke Simons Directorship.
"Surprising findings have implications for cancer immunotherapies that aim to harness the tumor-killing power of T cells, and they challenge existing ideas about how T cells become exhausted", said Mary Philip, MD, PhD, assistant professor of Medicine in the Division of Hematology and Oncology at Vanderbilt University Medical Center.
Advanced practice nurses, physician assistants and Medical Center leaders gathered in Light Hall on Jan. 17 for the kickoff of the 2023 series of Advanced Practice Grand Rounds, a monthly educational series organized by the Vanderbilt University Medical Center Office of Advanced Practice.
